September 03, 2024
A shareholder's certified class action against pharmaceutical company Teva can resume after being paused for two years, as the company says it is working towards a settlement with the U.S. Department of Justice over related claims it used kickbacks to raise the price of its multiple sclerosis drug Copaxone, a Philadelphia federal judge has decided.
May 16, 2024
The Third Circuit on Thursday turned away an appeal brought by Teva Pharmaceutical Industries Ltd., saying the class certification stage was not the right time to hear arguments over the "novel" question of the applicability of U.S. securities laws to Israeli-listed shares.
November 03, 2023
A Pennsylvania federal judge on Friday certified a class of Teva Pharmaceuticals investors who claim the company lied about illegal kickback payments it made to cover Medicare copayments of patients taking its multiple sclerosis drug.
March 25, 2022
A Pennsylvania federal judge Friday denied Teva Pharmaceuticals' motion to dismiss a proposed investor class action alleging the company lied about illegal kickback payments it made to cover Medicare copayments of patients taking its multiple sclerosis drug, saying the suit plausibly argues Teva wrongly attributed its success to "legitimate business factors."
March 26, 2021
Faruqi & Faruqi LLP was selected Friday to helm a putative investor class alleging that Teva Pharmaceuticals lied about illegal kickback payments it made to charitable foundations to cover Medicare copayments of patients taking its multiple sclerosis drug, according to an order filed in Pennsylvania federal court.